Stock listing

gettex:4A3 Immatics N.V. Aktie

German listing (gettex) of Immatics N.V. · home listing NASDAQ:IMTX

Follow Immatics N.V. into a list and get an email when it puts out news.

Home listing price · NASDAQ:IMTX

$5.77 USD -0.33 (-5.4%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:IMTX

Past year -42.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$5.72 – $5.95 USDNov 20, 2026
Volume
746,637 sharesNov 20, 2026
Market cap
$878.3M USDAt the close on Nov 20, 2026 · price × 152.2M shares outstanding
52-week range
$5.72 – $12.41 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$7.25M USDMedian day 761,100 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Immatics N.V. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:IMTX · Home$5.77 USD-0.33 (-5.4%)746,637$5.86$5.95$5.715$6.10Close on Nov 20, 2026
Frankfurt:4A3€5.32 EUR-0.195 (-3.5%)—€5.32€5.32€5.32€5.515Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IMTX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$5.77-0.33-5.4%$5.86$5.95$5.715746,637
$6.10-0.19-3.0%$6.27$6.41$6.061,571,164
$6.29+0.12+1.9%$6.27$6.31$6.063,164,202
$6.17-0.22-3.4%$6.33$6.57$6.07762,156
$6.39-0.13-2.0%$6.545$6.545$6.085586,384
$6.52-0.17-2.5%$6.64$6.89$6.34762,489
$6.69+0.27+4.2%$6.42$6.805$6.35964,298
$6.42-0.01-0.2%$6.32$6.78$6.201,221,136
$6.43+0.07+1.1%$6.47$6.635$6.301691,613
$6.36+0.18+2.9%$6.18$6.42$6.101,063,382
$6.18-0.73-10.6%$6.85$6.995$6.1451,278,128
$6.91-0.165-2.3%$7.25$7.515$6.89678,233
$7.075+0.015+0.2%$7.10$7.23$7.041,315,601
$7.06-0.14-1.9%$7.24$7.35$7.001,023,170
$7.20-0.11-1.5%$7.26$7.404$6.811,715,851
$7.31-0.04-0.5%$7.35$7.523$7.201,178,901
$7.35+0.09+1.2%$7.24$7.41$7.091,765,450
$7.26+0.11+1.5%$7.19$7.385$7.001,193,657
$7.15-0.16-2.2%$7.41$7.73$7.03756,066
$7.31-0.23-3.1%$7.46$7.50$7.25695,978
$7.54-0.15-2.0%$7.69$7.76$7.45621,016
$7.69+0.18+2.4%$7.62$7.95$7.611,980,384
$7.51+0.46+6.5%$7.07$7.605$6.9351,487,260
$7.05+0.32+4.8%$6.85$7.20$6.72967,122
$6.73-0.41-5.7%$7.19$7.19$6.651,154,900
$7.14+0.14+2.0%$7.05$7.21$6.9481,627,800
$7.00+0.17+2.5%$7.00$7.20$6.731,566,300
$6.83-0.38-5.3%$7.17$7.28$6.80928,000
$7.21-0.22-3.0%$7.41$7.42$7.14750,400
$7.43+0.06+0.8%$7.37$7.45$7.211,371,300
$7.37-0.08-1.1%$7.37$7.56$7.02604,700
$7.45-0.05-0.7%$7.44$7.70$7.31926,000
$7.50-0.23-3.0%$7.76$7.81$7.47974,400
$7.73+0.14+1.8%$7.57$7.85$7.47554,100
$7.59-0.85-10.1%$8.56$8.57$7.401,256,500
$8.44-0.34-3.9%$8.72$8.845$8.43639,700
$8.78+0.22+2.6%$8.56$9.16$8.431,898,600
$8.56+0.06+0.7%$8.50$8.695$8.39644,300
$8.50+0.13+1.6%$8.35$8.59$8.201,467,500
$8.37+0.04+0.5%$8.39$8.50$8.25378,800
$8.33-0.27-3.1%$8.52$8.571$8.062,372,900
$8.60-0.27-3.0%$8.80$8.89$8.575384,200
$8.87+0.15+1.7%$8.77$8.89$8.71501,600
$8.72+0.10+1.2%$8.76$8.87$8.58305,300
$8.62-0.20-2.3%$8.76$8.855$8.48759,900
$8.82+0.18+2.1%$8.97$9.04$8.74427,700
$8.64+0.04+0.5%$8.65$8.88$8.545711,900
$8.60-0.02-0.2%$8.59$8.77$8.335355,800
$8.62-0.17-1.9%$8.80$8.806$8.59378,600
$8.79+0.04+0.5%$8.84$8.921$8.535527,200
$8.75-0.36-4.0%$9.02$9.09$8.655798,800
$9.11-0.33-3.5%$9.38$9.555$9.085326,100
$9.44-0.12-1.3%$9.37$9.515$9.31699,500
$9.56+0.10+1.1%$9.34$9.57$9.30497,200
$9.46-0.04-0.4%$9.53$9.69$9.26494,300
$9.50+0.07+0.7%$9.47$9.723$9.295761,100
$9.43-0.10-1.0%$9.38$9.60$9.23607,100
$9.53+0.08+0.8%$9.36$9.55$9.231725,000
$9.45+0.09+1.0%$9.68$9.89$9.321,094,200
$9.36-0.07-0.7%$9.36$9.48$9.177742,200
$9.43+0.19+2.1%$9.22$9.465$8.97778,000
$9.24+0.55+6.3%$9.59$9.75$9.041,062,766
$8.69-0.24-2.7%$8.86$8.905$8.56338,149
$8.93+0.38+4.4%$8.60$9.05$8.60611,200
$8.55-0.70-7.6%$9.12$9.13$8.40474,800
Ticker
gettex:4A3
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
gettex
Currency
EUR

What changed lately

Latest news

All Immatics N.V. news

Immatics N.V. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
15 in the last 12 months · 80 in all · newest Nov 10, 2026 · oldest 2020
Decks
54 decks · latest Oct 26, 2026

Where Immatics N.V. is listed

ListingExchangeCountryCurrency
NASDAQ:IMTX · Home listingNASDAQUnited StatesUSD
Tradegate:4A3TradegateGermanyEUR
Frankfurt:4A3FrankfurtGermanyEUR
gettex:4A3 · This pagegettexGermanyEUR
LS Exchange:A2P72SLS ExchangeGermanyEUR
Lang & Schwarz:A2P72SLang & SchwarzGermanyEUR
Stuttgart:4A3StuttgartGermanyEUR
BOATS:IMTXBOATSUnited StatesUSD
Dusseldorf:4A3DusseldorfGermanyEUR
Hamburg:4A3HamburgGermanyEUR
Munich:4A3MunichGermanyEUR
Xetra:4A3XetraGermanyEUR
Hanover:4A3HanoverGermanyEUR

Valuation

EV/sales 7.9× against a median of 26.1×: 4th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$375.4M USD
P/E
Loss
EV/sales
7.9×
EV/EBITDA
Negative EBITDA
Price/book
1.8×
Gross margin
100.0%
Operating margin
−577.1%
Net margin
−534.1%
Debt to equity
0.0×
Beta vs S&P 500
1.40

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Immatics N.V. · NASDAQ:IMTXUS$878.3MUS$375.4Mn/a7.9×n/a1.8×−534.1%0.0×1.40
MoonLake Immunotherapeutics · NASDAQ:MLTXUS$942.1MUS$543.7Mn/an/an/a2.5×n/a0.3×1.32
Savara, Inc. · NASDAQ:SVRAUS$939.9MUS$840.4Mn/an/an/a8.7×n/a0.3×1.42
Metis TechBio Co., Ltd. Class H · HKEX:7666US$918.1MUS$487.6Mn/a223×n/a2.0×−373.2%0.0×n/a
InventisBio, Co., Ltd. Class A · SSE:688382US$897.5MUS$712.7Mn/a67.0×n/a4.6×−533.7%0.0×n/a
InnoCare Pharma Ltd. Class A · SSE:688428US$894.7M−US$209.0M9.3×−0.6×−2.3×0.8×27.1%0.1×n/a
Bio-Thera Solutions, Ltd. Class A · SSE:688177US$878.1MUS$924.2Mn/a5.9×n/a137×−42.0%14.3×n/a
Suzhou Ribo Life Science Co. Ltd. Class H · HKEX:6938US$875.5MUS$580.6Mn/a26.1×n/a3.4×−187.2%0.2×n/a
Aktis Oncology, Inc. · NASDAQ:AKTSUS$868.0MUS$385.9Mn/a31.2×n/a1.9×−706.8%0.0×1.21
Latigo Biotherapeutics, Inc. · NASDAQ:LTGOUS$861.9MUS$460.7Mn/an/an/a2.2×n/a0.0×n/a
Pharming Group NV · EURONEXT:PHARMUS$840.1MUS$766.3M34.4×2.0×19.8×2.9×6.3%0.4×n/a
Median of the othersUS$886.4MUS$562.1M21.9×26.1×8.7×2.7×−187.2%0.2×1.32

Forecasts

9 strong buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
16.40 USD · Analysts' mean
EPS, year to Dec 2026
-2.11 · 3 analysts
Revenue, year to Dec 2026
35.85M · 2 analysts

Team and board

Officers

OfficerRole
Harpreet SinghCo-Founder, Chief Executive Officer
Venkat RamananChief Financial Officer
Jim PepinGeneral Counsel, Corporate Secretary
Jürgen RichertVice President of Information Technology
Kerry SiegerVice President Global Quality Operations
Ali MohamedHead of Process Development
Amie KrauseChief People Officer
Andrea Mayer-MoklerHead of Clinical Development, Europe
Carsten ReinhardtChief Development Officer
Cedrik BrittenChief Medical Officer
Chris SealHead of National Accounts and Sales
Michael MølhøjHead of CMC Biologics
Miriam MeyerSenior Director and Head of Regulatory Affairs
Norbert HilfHead of Translational Development
Rainer KramerChief Business Officer
Steffen WalterChief Operations Officer
Toni WeinschenkChief Innovation Officer

Board

DirectorRole
Peter ChambréChair of the Board of Immatics N.V.
Adam StoneNon-Executive Director
Alise ReicinBoard Member
Eliot ForsterNon-Executive Director
Harpreet SinghCo-Founder, Chief Executive Officer
Heather L. MasonNon-Executive Director
Mathias HothumBoard Member
Michael G. AtiehNon-Executive Director
Paul CarterNon-Executive Director

Events

QuarterResultsShare move
Q3 2026Nov 10, 2026 · Before open−0.2%
Q2 2026Aug 18, 2026 · Before open−1.7%
Q1 2026May 12, 2026 · Before open−1.3%
Q4 2025Mar 25, 2026+6.2%
Q3 2025Nov 17, 2025 · Before open−7.2%
Q2 2025Aug 13, 2025 · Before open−5.0%
Q1 2025May 13, 2025 · Before open−4.8%
Q4 2024Mar 19, 2025 · Before open+5.1%
Q3 2024Nov 18, 2024 · Before open−4.3%
Q2 2024Aug 13, 2024 · Before open+1.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · Before open+5.5%
Q4 2023Mar 21, 2024 · Before open−5.9%
Q3 2023Nov 14, 2023 · Before open+1.5%
Q2 2023Aug 17, 2023 · Before open+1.9%
Q1 2023May 16, 2023 · Before open−2.0%
Q4 2022Mar 21, 2023 · Before open−0.8%
Q3 2022Nov 17, 2022 · Before open−0.5%
Q2 2022Aug 9, 2022 · Before open−3.6%
Q1 2022Jun 2, 2022 · Before open+3.2%
Q4 2021Mar 23, 2022 · Before open+1.8%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck63 slidesOct 26, 2026
Technical Presentation (October 2026)Technical29 slidesOct 26, 2026
Technical Presentation (October 2026)Technical23 slidesOct 23, 2026
Investor Presentation (August 2026)Investor deck59 slidesAug 18, 2026
Conference Presentation (June 2026)Conference25 slidesJun 1, 2026
Investor Presentation (March 2026)Investor deck54 slidesMar 5, 2026
Investor Presentation (January 2026)Investor deck54 slidesJan 12, 2026
Investor Presentation (December 2025)Investor deck54 slidesDec 11, 2025
Technical Presentation (December 2025)Technical18 slidesDec 11, 2025
2025 ESMO Immuno-Oncology CongressConference16 slidesDec 11, 2025
Show 50 decks
DeckKindSlidesDate
Investor Presentation (November 2025)Investor deck52 slidesNov 12, 2025
Technical Presentation (November 2025)Technical50 slidesNov 12, 2025
Investor Presentation (October 2025)Investor deck47 slidesOct 20, 2025
Presidential Symposium III, Proffered Paper #1600O (October 2025)Conference23 slidesOct 20, 2025
Investor Presentation (August 2025)Investor deck47 slidesAug 13, 2025
Technical Presentation (June 2025)Technical23 slidesJun 2, 2025
Investor Presentation (June 2025)Investor deck47 slidesJun 2, 2025
Investor Presentation (March 2025)Investor deck46 slidesMar 27, 2025
Investor Presentation (January 2025)Investor deck45 slidesJan 13, 2025
Investor Presentation (November 2024)Investor deck89 slidesNov 18, 2024
Technical Presentation (November 2024)Technical12 slidesNov 18, 2024
Investor Presentation (November 2024)Investor deck83 slidesNov 8, 2024
Investor Presentation (October 2024)Investor deck80 slidesOct 10, 2024
Society of Melanoma Research Congress 2024Conference28 slidesOct 10, 2024
Investor Presentation (September 2024)Investor deck72 slidesSep 16, 2024
European Society of Medical Oncology Congress 2024Conference30 slidesSep 16, 2024
Investor Presentation (May 2024)Investor deck65 slidesMay 14, 2024
Investor Presentation (March 2024)Investor deck73 slidesMar 21, 2024
Investor Presentation (January 2024)Investor deck75 slidesJan 22, 2024
Technical Presentation (November 2023)Technical55 slidesNov 8, 2023
Investor Presentation (November 2023)Investor deck75 slidesNov 8, 2023
Investor Presentation (September 2023)Investor deck71 slidesSep 11, 2023
Investor Presentation (August 2023)Investor deck69 slidesAug 17, 2023
Investor Presentation (May 2023)Investor deck67 slidesMay 2, 2023
Technical Presentation (May 2023)Technical26 slidesMay 2, 2023
Investor Presentation (March 2023)Investor deck60 slidesMar 21, 2023
Investor Presentation (January 2023)Investor deck59 slidesJan 9, 2023
Investor Presentation (November 2022)Investor deck60 slidesNov 17, 2022
Investor Presentation (October 2022)Investor deck61 slidesOct 18, 2022
Technical Presentation (October 2022)Technical25 slidesOct 11, 2022
Investor Presentation (June 2022)Investor deck54 slidesJun 30, 2022
Investor Presentation (June 2022)Investor deck54 slidesJun 2, 2022
Investor Presentation (May 2022)Investor deck53 slidesMay 18, 2022
Investor Presentation (May 2022)Investor deck53 slidesMay 10, 2022
Investor Presentation (March 2022)Investor deck50 slidesMar 23, 2022
Investor Presentation (December 2021)Investor deck47 slidesDec 14, 2021
Investor Presentation (November 2021)Investor deck46 slidesNov 9, 2021
Corporate Update (November 2021)Corporate update35 slidesNov 9, 2021
Investor Presentation (July 2021)Investor deck37 slidesJul 15, 2021
PEGS: The Essential Protein Engineering & Cell Therapy Summit 2021Conference10 slidesMay 11, 2021

This page holds 50 of 54 decks. Open Decks

Open Decks

Financings

RaiseDate
Public offering of ordinary shares and pre-funded warrants
Announced: US$150M · US$8.69 a share · Jefferies +2
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Cantor (co-lead)
Aug 25, 2026
Public offering of ordinary shares
Announced: US$125M · US$10 a share · Jefferies +2
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Cantor (co-lead)
Dec 5, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in EUR

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue48.3M155.8M54.0M172.8M34.8M31.3M18.4M3.77M
Cost of revenue148.1M118.7M106.8M87.6M67.1M40.1M34.0M
Gross profit48.3M155.8M54.0M172.8M34.8M-35.8M-21.6M-30.2M
Research and development183.8M148.1M118.7M106.8M87.6M67.1M40.1M34.0M
Selling, general and administrative51.2M46.4M38.2M36.1M33.8M34.1M11.8M7.67M
Operating income-182.0M-38.6M-101.7M30.0M-86.3M-69.7M-33.0M-34.4M
Depreciation and amortization12.4M12.2M7.23M6.97M5.26M4.42M3.86M2.18M
EBITDA-169.6M-26.4M-94.5M36.9M-81.0M-65.3M-29.2M-32.2M
Interest expense946.0K886.0K831.0K1.04M566.0K289.0K264.0K161.0K
Income before tax-198.4M21.3M-97.0M42.0M-93.3M-211.8M-32.5M-32.4M
Income tax-1.99M6.13M-2.35M14.3M0000
Net income-196.4M15.2M-94.6M27.7M-93.3M-211.3M-31.6M-31.4M
Earnings per share, basic-1.610.14-1.180.41-1.48-4.40-0.50-0.50
Earnings per share, diluted-1.610.14-1.180.40-1.48-4.40

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents345.9M236.7M218.5M148.5M133.0M207.5M103.4M39.4M
Short-term investments123.4M367.7M207.4M213.7M12.1M24.4M16.0M13.1M
Receivables6.10M5.86M4.09M1.11M682.0K1.25M957.0K1.82M
Inventory1113.30M1.24M1
Current assets504.0M629.6M449.4M377.2M152.2M239.0M124.0M55.3M
Property, plant and equipment42.1M50.4M43.7M13.5M10.5M7.87M4.72M4.01M
Total assets562.3M696.1M510.0M407.8M174.6M254.6M134.3M61.3M
Accounts payable18.8M20.7M25.2M13.1M11.6M10.1M7.08M4.80M
Current liabilities43.0M68.0M156.6M106.5M95.1M77.5M69.3M26.8M
Total debt15.6M16.2M15.4M14.6M9.85M6.19M3.23M
Total liabilities78.2M121.3M292.3M204.5M150.6M167.3M175.1M70.5M
Shareholders' equity484.1M574.8M217.6M203.4M24.1M87.4M-41.9M-9.17M
Shares outstanding122.3M106.8M80.5M68.2M62.9M62.9M62.9M62.9M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-176.6M-158.0M18.2M100.1M-84.7M-80.7M71.0M20.7M
Capital spending-6.56M-16.3M-30.8M-5.74M-5.11M-7.42M-2.14M-429.0K
Free cash flow-183.2M-174.3M-12.6M94.4M-89.9M-88.1M68.8M20.3M
Cash from investing204.8M-152.4M-31.4M-209.8M7.49M-15.9M-5.06M-13.5M
Cash from financing97.4M319.7M84.5M123.7M-2.61M207.9M-1.86M23.6M
Share buybacks149.7M
Change in cash125.5M9.27M71.4M14.1M-79.9M111.2M64.0M30.8M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 20, 2026Insider tradeSEC
144 · Notice of proposed saleNov 19, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerNov 10, 2026Current reportSEC
6-K · Report of a foreign issuerOct 26, 2026Current reportSEC
6-K · Report of a foreign issuerOct 23, 2026Current reportSEC
4 · Change in ownershipAug 27, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13D/A · Big-stake notice, amendedAug 27, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerAug 26, 2026Current reportSEC
424B2 · ProspectusAug 25, 2026Offer documentSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
6-K · Report of a foreign issuerAug 18, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
3 · Initial statement of ownershipJul 29, 2026Insider tradeSEC
S-8 · Registration statement for employee plansJun 25, 2026Offer documentSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
6-K · Report of a foreign issuerJun 18, 2026Current reportSEC
6-K · Report of a foreign issuerJun 2, 2026Current reportSEC
6-K · Report of a foreign issuerJun 1, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerMay 12, 2026Current reportSEC
6-K · Report of a foreign issuerApr 21, 2026Current reportSEC
6-K · Report of a foreign issuerApr 17, 2026Current reportSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 17, 2026Insider tradeSEC
20-F · Annual reportMar 5, 2026Annual reportSEC
6-K · Report of a foreign issuerMar 5, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerJan 12, 2026Current reportSEC
6-K · Report of a foreign issuerDec 11, 2025Current reportSEC
6-K · Report of a foreign issuerDec 8, 2025Current reportSEC
424B5 · ProspectusDec 5, 2025Offer documentSEC
424B5 · ProspectusDec 4, 2025Offer documentSEC
6-K · Report of a foreign issuerNov 17, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerNov 12, 2025Current reportSEC
6-K · Report of a foreign issuerOct 27, 2025Current reportSEC
6-K · Report of a foreign issuerOct 20, 2025Current reportSEC
6-K · Report of a foreign issuerOct 1, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerAug 13, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansJul 1, 2025Offer documentSEC
25-NSEJun 30, 2025Other filingsSEC
6-K · Report of a foreign issuerJun 18, 2025Current reportSEC
6-K · Report of a foreign issuerJun 2, 2025Current reportSEC
6-K · Report of a foreign issuerJun 2, 2025Current reportSEC
6-K · Report of a foreign issuerMay 13, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 2, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveApr 4, 2025Other filingsSEC
CORRESP · Letter to the SECApr 1, 2025Other filingsSEC
UPLOAD · Letter from the SECApr 1, 2025Other filingsSEC
F-3 · Registration statementMar 27, 2025Offer documentSEC
6-K · Report of a foreign issuerMar 27, 2025Current reportSEC
20-F · Annual reportMar 27, 2025Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 7, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 11, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerJan 13, 2025Current reportSEC
6-K · Report of a foreign issuerDec 13, 2024Current reportSEC
6-K · Report of a foreign issuerNov 18, 2024Current reportSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerNov 8, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 8, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedOct 17, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerOct 15, 2024Current reportSEC
424B2 · ProspectusOct 11, 2024Offer documentSEC
424B2 · ProspectusOct 10, 2024Offer documentSEC
F-3ASROct 10, 2024Other filingsSEC
6-K · Report of a foreign issuerOct 10, 2024Current reportSEC
6-K · Report of a foreign issuerSep 16, 2024Current reportSEC
6-K · Report of a foreign issuerAug 13, 2024Current reportSEC
6-K · Report of a foreign issuerJul 31, 2024Current reportSEC
S-8 · Registration statement for employee plansJul 22, 2024Offer documentSEC
6-K · Report of a foreign issuerJun 20, 2024Current reportSEC
SC 13D · Big-stake noticeJun 6, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJun 6, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerJun 3, 2024Current reportSEC
6-K · Report of a foreign issuerMay 14, 2024Current reportSEC
6-K · Report of a foreign issuerMar 21, 2024Current reportSEC
20-F · Annual reportMar 21, 2024Annual reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 8, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 7, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 7, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerJan 22, 2024Current reportSEC
424B5 · ProspectusJan 19, 2024Offer documentSEC
424B5 · ProspectusJan 17, 2024Offer documentSEC
6-K · Report of a foreign issuerNov 14, 2023Current reportSEC
6-K · Report of a foreign issuerNov 8, 2023Current reportSEC
6-K · Report of a foreign issuerOct 24, 2023Current reportSEC
EFFECT · Notice that a registration is effectiveSep 14, 2023Other filingsSEC
424B3 · ProspectusSep 13, 2023Offer documentSEC
CORRESP · Letter to the SECSep 11, 2023Other filingsSEC
6-K · Report of a foreign issuerSep 11, 2023Current reportSEC
UPLOAD · Letter from the SECAug 29, 2023Other filingsSEC
F-3 · Registration statementAug 25, 2023Offer documentSEC
6-K · Report of a foreign issuerAug 17, 2023Current reportSEC
SC 13G · Big-stake noticeAug 16, 2023Big-stake noticeSEC
6-K · Report of a foreign issuerAug 10, 2023Current reportSEC
6-K · Report of a foreign issuerJul 24, 2023Current reportSEC
6-K · Report of a foreign issuerJun 20, 2023Current reportSEC
6-K · Report of a foreign issuerMay 26, 2023Current reportSEC
6-K · Report of a foreign issuerMay 16, 2023Current reportSEC
6-K · Report of a foreign issuerMay 2, 2023Current reportSEC
6-K · Report of a foreign issuerMay 1, 2023Current reportSEC
20-F · Annual reportMar 22, 2023Annual reportSEC
6-K · Report of a foreign issuerMar 21, 2023Current reportSEC
6-K · Report of a foreign issuerMar 13, 2023Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 10, 2023Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 6, 2023Big-stake noticeSEC
6-K · Report of a foreign issuerJan 9, 2023Current reportSEC
6-K · Report of a foreign issuerNov 17, 2022Current reportSEC
6-K · Report of a foreign issuerNov 10, 2022Current reportSEC
6-K · Report of a foreign issuerOct 18, 2022Current reportSEC
6-K · Report of a foreign issuerOct 12, 2022Current reportSEC
424B5 · ProspectusOct 11, 2022Offer documentSEC
424B5 · ProspectusOct 11, 2022Offer documentSEC
6-K · Report of a foreign issuerOct 11, 2022Current reportSEC
6-K · Report of a foreign issuerSep 12, 2022Current reportSEC
6-K · Report of a foreign issuerAug 23, 2022Current reportSEC
6-K · Report of a foreign issuerAug 9, 2022Current reportSEC
6-K · Report of a foreign issuerJun 30, 2022Current reportSEC
S-8 · Registration statement for employee plansJun 24, 2022Offer documentSEC
6-K · Report of a foreign issuerJun 14, 2022Current reportSEC
6-K · Report of a foreign issuerJun 13, 2022Current reportSEC
6-K · Report of a foreign issuerJun 7, 2022Current reportSEC
6-K · Report of a foreign issuerJun 2, 2022Current reportSEC
6-K · Report of a foreign issuerJun 2, 2022Current reportSEC
6-K · Report of a foreign issuerMay 27, 2022Current reportSEC
6-K · Report of a foreign issuerMay 18, 2022Current reportSEC
6-K · Report of a foreign issuerMay 10, 2022Current reportSEC
20-F · Annual reportMar 23, 2022Annual reportSEC
6-K · Report of a foreign issuerMar 23, 2022Current reportSEC
SC 13G · Big-stake noticeFeb 14, 2022Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2022Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 11, 2022Big-stake noticeSEC
6-K · Report of a foreign issuerDec 14, 2021Current reportSEC
6-K · Report of a foreign issuerNov 16, 2021Current reportSEC
6-K · Report of a foreign issuerNov 9, 2021Current reportSEC
6-K · Report of a foreign issuerNov 1, 2021Current reportSEC
6-K/A · Report of a foreign issuer, amendedOct 28, 2021Current reportSEC
6-K/A · Report of a foreign issuer, amendedOct 28, 2021Current reportSEC
20-F/A · Annual report, amendedOct 28, 2021Annual reportSEC
6-K · Report of a foreign issuerAug 10, 2021Current reportSEC
EFFECT · Notice that a registration is effectiveAug 10, 2021Other filingsSEC
CORRESP · Letter to the SECAug 6, 2021Other filingsSEC
UPLOAD · Letter from the SECAug 6, 2021Other filingsSEC
EFFECT · Notice that a registration is effectiveAug 6, 2021Other filingsSEC
POS AM · Amendment to an effective registrationAug 2, 2021Offer documentSEC
F-3 · Registration statementAug 2, 2021Offer documentSEC
UPLOAD · Letter from the SECJul 30, 2021Other filingsSEC
CORRESP · Letter to the SECJul 21, 2021Other filingsSEC
6-K · Report of a foreign issuerJul 15, 2021Current reportSEC
UPLOAD · Letter from the SECJul 1, 2021Other filingsSEC
424B3 · ProspectusJun 22, 2021Offer documentSEC
6-K · Report of a foreign issuerJun 22, 2021Current reportSEC
424B3 · ProspectusMay 26, 2021Offer documentSEC

This page holds 200 of 250 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Immatics N.V.’s releases · as of Aug 25, 2026

Common shares
152,225,077
Fully diluted
152,225,077

Fully diluted

LineShares
Common shares152,225,077

Share count over time

CountShares
Nov 22, 2026152,225,077

Open Cap table

Shareholders

Funds

HolderSharesValueAs of
T. Rowe Price Small-Cap Stock Fund, Inc.5.24MUS$53.1MJun 30, 2026
T. Rowe Price Small-Cap Value Fund, Inc.5.17MUS$52.3MJun 30, 2026
T. Rowe Price Institutional Small-Cap Stock Fund2.85MUS$28.9MJun 30, 2026
Wasatch Ultra Growth Fund431KUS$4.37MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.321KUS$3.26MJun 30, 2026
Small Cap Value Portfolio287KUS$2.91MJun 30, 2026
Vanguard International Explorer Fund221KUS$1.92MJul 31, 2026
State Street(R) SPDR(R) Portfolio Developed World ex-US ETF192KUS$1.95MJun 30, 2026
State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF181KUS$1.83MJun 30, 2026
T. Rowe Price Spectrum Moderate Growth Allocation Fund174KUS$2MMay 31, 2026
All 31 holders
HolderSharesValueAs of
Tema Oncology ETF171KUS$1.97MMay 31, 2026
ALPS Medical Breakthroughs ETF138KUS$1.59MMay 31, 2026
Fidelity Nasdaq Composite Index Fund80,545US$927KMay 31, 2026
Nationwide International Small Cap Fund65,689US$569KJul 31, 2026
Small Company Value Trust64,404US$652KJun 30, 2026
T. Rowe Price Spectrum Moderate Allocation Fund62,619US$721KMay 31, 2026
Fidelity Nasdaq Composite Index ETF60,449US$696KMay 31, 2026
State Street(R) SPDR(R) S&P(R) International Small Cap ETF46,668US$473KJun 30, 2026
T. Rowe Price Spectrum Conservative Allocation Fund40,893US$471KMay 31, 2026
Virtus Biotech Clinical Trials Etf33,135US$287KJul 31, 2026
International Opportunities Fund31,377US$361KMay 31, 2026
T. Rowe Price Health Sciences Portfolio20,700US$210KJun 30, 2026
T. Rowe Price Health Care ETF19,722US$200KJun 30, 2026
Health Sciences Trust11,700US$119KJun 30, 2026
Goldman Sachs Absolute Return Tracker Fund9,268US$93,885Jun 30, 2026
EQ/T.Rowe Price Health Sciences Portfolio8,500US$86,105Jun 30, 2026
T. Rowe Price Moderate Allocation Portfolio6,811US$68,995Jun 30, 2026
Small Cap Core Fund6,320US$64,022Jun 30, 2026
Innovator U.S. Small Cap Managed Floor ETF5,446US$47,162Jul 31, 2026
Total Stock Market Index Trust2,221US$22,499Jun 30, 2026
Innovator U.S. Small Cap Managed 10 Buffer ETF976US$8,452Jul 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Kramer Rainer
Officer: Chief Business Officer
Sale22,868USD 6.06US$139KNov 19, 2026
Joseph Edelman
Director
Buy863,060USD 8.69US$7.5MAug 26, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Michael G. Atieh
Other companies: Chubb Limited (Director · Since at least May 19, 2010); Oyster Point Pharma Inc (Director · Oct 8, 2020 – Jan 3, 2023 · Past); electroCore, Inc. (Director · Jun 21, 2018 – Jun 11, 2021 · Past); IVERIC bio Inc (EVP, CFO, & CBO, Treasurer · Sep 30, 2014 – Jan 2, 2016 · Past); Theravance Biopharma, Inc. (Director · Jun 3, 2014 – Jun 3, 2014 · Past)
Non-Executive Director · Since at least Mar 18, 2026
Alise Reicin
Other companies: Tectonic Therapeutic, Inc. (President and CEO, Director · Since at least Jun 20, 2024); Sana Biotechnology, Inc. (Director · Since at least Feb 3, 2021); Q32 Bio Inc. (Director · Jul 11, 2019 – Jun 14, 2023 · Past); Celgene Corporation (PRES., GLOBAL CLINICAL DEV. · Nov 1, 2018 – Nov 20, 2019 · Past)
Director · Since at least Mar 18, 2026
Paul Carter
Other companies: Mallinckrodt Inc (Director · May 16, 2018 – Jun 16, 2022 · Past); Alder BioPharmaceuticals Inc (Director · Sep 28, 2015 – Oct 22, 2019 · Past); Gilead Sciences, Inc. (EVP Commercial Ops · Jul 1, 2015 – Aug 1, 2016 · Past)
Non-Executive Director · Since at least Mar 18, 2026
Joseph Edelman
Other companies: Kardigan, Inc. (Director · Since at least Jun 17, 2026)
Director · Since at least Aug 26, 2026
Adam StoneNon-Executive Director · Since at least Nov 5, 2026
Ali MohamedHead of Process Development · Since at least Nov 4, 2026
Amie KrauseChief People Officer · Since at least Mar 5, 2026
Andrea Mayer-MoklerHead of Clinical Development, Europe · Since at least Nov 4, 2026
Carsten ReinhardtChief Development Officer · Since at least Mar 18, 2026
Cedrik BrittenChief Medical Officer · Since at least Oct 24, 2026
All 31 people
PersonSeat
Cedrik Michael BrittenChief Medical Officer · Since at least Mar 18, 2026
Chris SealHead of National Accounts and Sales · Since at least Nov 4, 2026
Edward A Sturchio JrGeneral Counsel · Since at least Mar 18, 2026
Eliot ForsterNon-Executive Director · Since at least Nov 5, 2026
Harpreet SinghCo-Founder, Chief Executive Officer · Since at least Aug 18, 2026
Heather L. MasonNon-Executive Director · Since at least Nov 5, 2026
James Nelson PepinGen Counsel and Corp Secretary · Since at least Jul 20, 2026
Jasuja Harpreet SinghChief Executive Officer, Director · Since at least Mar 18, 2026
Jim PepinGeneral Counsel, Corporate Secretary · Since at least Aug 18, 2026
Jordan Zeik SilversteinHead of Strategy · Since at least Mar 18, 2026
Jürgen RichertVice President of Information Technology · Since at least Nov 5, 2026
Kerry SiegerVice President Global Quality Operations · Since at least Nov 5, 2026
Mathias HothumBoard Member · Since at least Mar 17, 2026
Michael MølhøjHead of CMC Biologics · Since at least Nov 5, 2026
Miriam MeyerSenior Director and Head of Regulatory Affairs · Since at least Nov 5, 2026
Norbert HilfHead of Translational Development · Since at least Nov 4, 2026
Peter ChambréChair of the Board of Immatics N.V. · Since at least Mar 18, 2026
Rainer KramerChief Business Officer · Since at least Mar 18, 2026
Steffen WalterChief Operations Officer · Since at least Nov 5, 2026
Toni WeinschenkChief Innovation Officer · Since at least Mar 18, 2026
Venkat RamananChief Financial Officer · Since at least Mar 5, 2026

Open People

Log in to ask 6ix AI your own questions about Immatics N.V.